What is a 510(k) submission?

A 510(k) is a premarket notification process required by the FDA for medical devices. It demonstrates that the device to be marketed is as safe and effective (substantially equivalent) as a legally marketed device that is not subject to premarket approval.

What is the BD Alaris™ System?

The BD Alaris™ System is a modular drug delivery platform that helps healthcare professionals provide safe and effective patient care. It is used for various infusion and injection therapies.

What does it mean that the submission addresses 'open recall issues'?

This indicates that BDX is proactively working to resolve previously identified safety or performance issues with the Alaris System that may have led to past recalls or regulatory actions. The new software aims to rectify these issues.

What is the potential impact of this 510(k) submission on BDX investors?

Successful clearance of this 510(k) submission is positive for investors as it indicates BDX is addressing regulatory and product performance issues, which can help maintain market access, improve product reliability, and reduce potential liabilities associated with the Alaris System.

BDX 8-K: Regulation FD — Apr 26, 2021

Summary

Becton, Dickinson and Company (BDX) announced on April 26, 2021, that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its BD Alaris™ System. This submission is a critical step to update the regulatory clearance for the Alaris System, a key medical device for the company. The update aims to incorporate new features and address previously identified recall issues, signaling proactive management of product lifecycle and safety concerns. The 510(k) submission includes a new version of the BD Alaris™ System software, which will bring significant clinical, operational, and cybersecurity enhancements. For investors, this development suggests BDX is committed to maintaining the compliance and performance of its product portfolio, potentially mitigating future regulatory risks and ensuring continued market access for a significant revenue-generating platform. The company is actively working to resolve outstanding issues and improve its core offerings.

Key Highlights

1BDX submitted a 510(k) premarket notification to the FDA for the BD Alaris™ System.
2The submission aims to update the regulatory clearance for the Alaris System.
3A new version of the BD Alaris™ System software is part of this submission.
4The updated software will include clinical, operational, and cybersecurity enhancements.
5This action addresses open recall issues associated with the Alaris System.
6The filing indicates BDX is actively managing product lifecycle and regulatory compliance.

BECTON DICKINSON & CO 8-K Report, Regulation FD Disclosure (Apr 26, 2021)

Summary

Key Highlights

Frequently Asked Questions